Skip to main content
Erschienen in: Annals of Surgical Oncology 1/2015

01.01.2015 | Breast Oncology

Breast Conservation in the Setting of Contemporary Multimodality Treatment Provides Excellent Outcomes for Patients with Occult Primary Breast Cancer

verfasst von: Natasha M. Rueth, MD, MS, Dalliah M. Black, MD, Angela R. Limmer, MS, PA, Emmanuel Gabriel, MD, PhD, Lei Huo, MD, Bruno D. Fornage, MD, Basak E. Dogan, MD, Mariana Chavez-MacGregor, MD, MS, Min Yi, MD, PhD, Kelly K. Hunt, MD, Eric A. Strom, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate recurrence and survival for patients with occult (T0N+) breast cancer who underwent contemporary treatment, assessing outcomes for breast conservation and mastectomy.

Methods

We performed a single-institution review of women with occult breast cancer presenting with axillary metastasis without identifiable breast tumor or distant metastasis. We excluded patients with tumors in the axillary tail or mastectomy specimen, patients with additional nonbreast cancer diagnoses, and patients with a history of breast cancer. Breast conservation was defined as axillary node dissection with radiation therapy, without breast surgery. We evaluated patient, tumor, treatment, and outcome variables. Patients were assessed for local, regional, and distant recurrences. Overall survival was calculated using the Kaplan–Meier method.

Results

Thirty-six patients met criteria for occult breast cancer. Most of these patients (77.8 %) had N1 disease. Fifty percent of cancers (n = 18) were estrogen receptor–positive; 12 (33.3 %) were triple-negative. All patients were evaluated with mammography. Thirty-five patients had breast ultrasound (97.2 %) and 33 (91.7 %) had an MRI. Thirty-four patients (94.4 %) were treated with chemotherapy and 33 (91.7 %) with radiotherapy. Twenty-seven patients (75.0 %) were treated with breast conservation. The median follow-up was 64 months. There were no local or regional failures. One distant recurrence occurred >5 years after diagnosis, resulting in a 5-years overall survival rate of 100 %. There were no significant survival differences between patients receiving breast conservation versus mastectomy (p = 0.7).

Conclusions

Breast conservation—performed with contemporary imaging and multimodality treatment—provides excellent local control and survival for women with T0N+ breast cancer and can be safely offered instead of mastectomy.
Literatur
1.
Zurück zum Zitat Baron PL, Moore MP, Kinne DW, et al. Occult breast cancer presenting with axillary metastases. Updated management. Arch Surg. 1990;125:210–4.CrossRef Baron PL, Moore MP, Kinne DW, et al. Occult breast cancer presenting with axillary metastases. Updated management. Arch Surg. 1990;125:210–4.CrossRef
2.
Zurück zum Zitat Kemeny MM, Rivera DE, Terz JJ, Benfield JR. Occult primary adenocarcinoma with axillary metastases. Am J Surg. 1986;152:43–7.PubMedCrossRef Kemeny MM, Rivera DE, Terz JJ, Benfield JR. Occult primary adenocarcinoma with axillary metastases. Am J Surg. 1986;152:43–7.PubMedCrossRef
3.
4.
Zurück zum Zitat Rosen PP, Kimmel M. Occult breast carcinoma presenting with axillary lymph node metastases: a follow-up study of 48 patients. Hum Pathol. 1990;21:518–23.PubMedCrossRef Rosen PP, Kimmel M. Occult breast carcinoma presenting with axillary lymph node metastases: a follow-up study of 48 patients. Hum Pathol. 1990;21:518–23.PubMedCrossRef
6.
Zurück zum Zitat Khandelwal AK, Garguilo GA. Therapeutic options for occult breast cancer: a survey of the American Society of Breast Surgeons and review of the literature. Am J Surg. 2005;190:609–13.PubMedCrossRef Khandelwal AK, Garguilo GA. Therapeutic options for occult breast cancer: a survey of the American Society of Breast Surgeons and review of the literature. Am J Surg. 2005;190:609–13.PubMedCrossRef
7.
Zurück zum Zitat Lanitis S, Behranwala KA, Al-Mufti R, Hadjiminas D. Axillary metastatic disease as presentation of occult or contralateral breast cancer. Breast. 2009;18:225–7.PubMedCrossRef Lanitis S, Behranwala KA, Al-Mufti R, Hadjiminas D. Axillary metastatic disease as presentation of occult or contralateral breast cancer. Breast. 2009;18:225–7.PubMedCrossRef
8.
Zurück zum Zitat Walker GV, Smith GL, Perkins GH, et al. Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer. 2010;116:4000–6.PubMedCrossRef Walker GV, Smith GL, Perkins GH, et al. Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer. 2010;116:4000–6.PubMedCrossRef
10.
Zurück zum Zitat Ellerbroek N, Holmes F, Singletary E, et al. Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin. Cancer. 1990;66:1461–7.PubMedCrossRef Ellerbroek N, Holmes F, Singletary E, et al. Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin. Cancer. 1990;66:1461–7.PubMedCrossRef
11.
Zurück zum Zitat Merson M, Andreola S, Galimberti V, et al. Breast carcinoma presenting as axillary metastases without evidence of a primary tumor. Cancer. 1992;70:504–8.PubMedCrossRef Merson M, Andreola S, Galimberti V, et al. Breast carcinoma presenting as axillary metastases without evidence of a primary tumor. Cancer. 1992;70:504–8.PubMedCrossRef
12.
Zurück zum Zitat Valero V, Buzdar AU, McNeese M, et al. Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience. Clin Breast Cancer. 2002;3 Suppl 2:S63–8.PubMedCrossRef Valero V, Buzdar AU, McNeese M, et al. Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience. Clin Breast Cancer. 2002;3 Suppl 2:S63–8.PubMedCrossRef
13.
Zurück zum Zitat Cance WG, Carey LA, Calvo BF, et al. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Ann Surg. 2002;236:295–302; discussion 293–302. Cance WG, Carey LA, Calvo BF, et al. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Ann Surg. 2002;236:295–302; discussion 293–302.
14.
Zurück zum Zitat Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41.PubMedCrossRef Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41.PubMedCrossRef
15.
Zurück zum Zitat Brill KL, Brenin DR. Occult breast cancer and axillary mass. Curr Treat Options Oncol. 2001;2:149–55.PubMedCrossRef Brill KL, Brenin DR. Occult breast cancer and axillary mass. Curr Treat Options Oncol. 2001;2:149–55.PubMedCrossRef
16.
Zurück zum Zitat Foroudi F, Tiver KW. Occult breast carcinoma presenting as axillary metastases. Int J Radiat Oncol Biol Phys. 2000;47:143–7.PubMedCrossRef Foroudi F, Tiver KW. Occult breast carcinoma presenting as axillary metastases. Int J Radiat Oncol Biol Phys. 2000;47:143–7.PubMedCrossRef
17.
Zurück zum Zitat Shannon C, Walsh G, Sapunar F, et al. Occult primary breast carcinoma presenting as axillary lymphadenopathy. Breast. 2002;11:414–8.PubMedCrossRef Shannon C, Walsh G, Sapunar F, et al. Occult primary breast carcinoma presenting as axillary lymphadenopathy. Breast. 2002;11:414–8.PubMedCrossRef
18.
Zurück zum Zitat Vlastos G, Jean ME, Mirza AN et al. Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol. 2001;8:425–431.PubMedCrossRef Vlastos G, Jean ME, Mirza AN et al. Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol. 2001;8:425–431.PubMedCrossRef
19.
Zurück zum Zitat Fowble B, Gray R, Gilchrist K, et al. Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy. J Clin Oncol 1988;6:1107–17.PubMed Fowble B, Gray R, Gilchrist K, et al. Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy. J Clin Oncol 1988;6:1107–17.PubMed
20.
Zurück zum Zitat Whillis D, Brown PW, Rodger A. Adenocarcinoma from an unknown primary presenting in women with an axillary mass. Clin Oncol (R Coll Radiol). 1990;2:189–92.PubMedCrossRef Whillis D, Brown PW, Rodger A. Adenocarcinoma from an unknown primary presenting in women with an axillary mass. Clin Oncol (R Coll Radiol). 1990;2:189–92.PubMedCrossRef
21.
Zurück zum Zitat Buchanan CL, Morris EA, Dorn PL, et al. Utility of breast magnetic resonance imaging in patients with occult primary breast cancer. Ann Surg Oncol. 2005;12:1045–53.PubMedCrossRef Buchanan CL, Morris EA, Dorn PL, et al. Utility of breast magnetic resonance imaging in patients with occult primary breast cancer. Ann Surg Oncol. 2005;12:1045–53.PubMedCrossRef
22.
Zurück zum Zitat Chen C, Orel SG, Harris E, et al. Outcome after treatment of patients with mammographically occult, magnetic resonance imaging-detected breast cancer presenting with axillary lymphadenopathy. Clin Breast Cancer. 2004;5:72–7.PubMedCrossRef Chen C, Orel SG, Harris E, et al. Outcome after treatment of patients with mammographically occult, magnetic resonance imaging-detected breast cancer presenting with axillary lymphadenopathy. Clin Breast Cancer. 2004;5:72–7.PubMedCrossRef
23.
Zurück zum Zitat McMahon K, Medoro L, Kennedy D. Breast magnetic resonance imaging: an essential role in malignant axillary lymphadenopathy of unknown origin. Australas Radiol. 2005;49:382–9.PubMedCrossRef McMahon K, Medoro L, Kennedy D. Breast magnetic resonance imaging: an essential role in malignant axillary lymphadenopathy of unknown origin. Australas Radiol. 2005;49:382–9.PubMedCrossRef
24.
Zurück zum Zitat Morris EA, Schwartz LH, Dershaw DD et al. MR imaging of the breast in patients with occult primary breast carcinoma. Radiology. 1997;205:437–40.PubMedCrossRef Morris EA, Schwartz LH, Dershaw DD et al. MR imaging of the breast in patients with occult primary breast carcinoma. Radiology. 1997;205:437–40.PubMedCrossRef
25.
Zurück zum Zitat Obdeijn IM, Brouwers-Kuyper EM, Tilanus-Linthorst MM, et al. MR imaging-guided sonography followed by fine-needle aspiration cytology in occult carcinoma of the breast. AJR Am J Roentgenol. 2000;174:1079–84.PubMedCrossRef Obdeijn IM, Brouwers-Kuyper EM, Tilanus-Linthorst MM, et al. MR imaging-guided sonography followed by fine-needle aspiration cytology in occult carcinoma of the breast. AJR Am J Roentgenol. 2000;174:1079–84.PubMedCrossRef
26.
Zurück zum Zitat Olson JA Jr., Morris EA, Van Zee KJ et al. Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol. 2000;7:411–5.PubMedCrossRef Olson JA Jr., Morris EA, Van Zee KJ et al. Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol. 2000;7:411–5.PubMedCrossRef
27.
Zurück zum Zitat Orel SG, Weinstein SP, Schnall MD et al. Breast MR imaging in patients with axillary node metastases and unknown primary malignancy. Radiology. 1999;212:543–9.PubMedCrossRef Orel SG, Weinstein SP, Schnall MD et al. Breast MR imaging in patients with axillary node metastases and unknown primary malignancy. Radiology. 1999;212:543–9.PubMedCrossRef
28.
Zurück zum Zitat Vilcoq JR, Calle R, Ferme F, Veith F. Conservative treatment of axillary adenopathy due to probable subclinical breast cancer. Arch Surg. 1982;117:1136–8.PubMedCrossRef Vilcoq JR, Calle R, Ferme F, Veith F. Conservative treatment of axillary adenopathy due to probable subclinical breast cancer. Arch Surg. 1982;117:1136–8.PubMedCrossRef
Metadaten
Titel
Breast Conservation in the Setting of Contemporary Multimodality Treatment Provides Excellent Outcomes for Patients with Occult Primary Breast Cancer
verfasst von
Natasha M. Rueth, MD, MS
Dalliah M. Black, MD
Angela R. Limmer, MS, PA
Emmanuel Gabriel, MD, PhD
Lei Huo, MD
Bruno D. Fornage, MD
Basak E. Dogan, MD
Mariana Chavez-MacGregor, MD, MS
Min Yi, MD, PhD
Kelly K. Hunt, MD
Eric A. Strom, MD
Publikationsdatum
01.01.2015
Verlag
Springer US
Erschienen in
Annals of Surgical Oncology / Ausgabe 1/2015
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3991-0

Weitere Artikel der Ausgabe 1/2015

Annals of Surgical Oncology 1/2015 Zur Ausgabe

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

Real-World-Daten sprechen eher für Dupilumab als für Op.

14.05.2024 Rhinosinusitis Nachrichten

Zur Behandlung schwerer Formen der chronischen Rhinosinusitis mit Nasenpolypen (CRSwNP) stehen seit Kurzem verschiedene Behandlungsmethoden zur Verfügung, darunter Biologika, wie Dupilumab, und die endoskopische Sinuschirurgie (ESS). Beim Vergleich der beiden Therapieoptionen war Dupilumab leicht im Vorteil.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.